Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ALEXION PHARMACEUTICALS, INC.

(ALXN)
  Report
 SummaryQuotesChartsNewsRatingsCompanyFinancials 
Estimated financial data (e) (USD)
Sales 2019 4 991 M - -
Net income 2019 2 404 M - -
Net Debt 2019 74,6 M - -
P/E ratio 2019 10,1x
Yield 2019 -
Sales 2020 6 070 M - -
Net income 2020 603 M - -
Net cash position 2020 68,0 M - -
P/E ratio 2020 57,4x
Yield 2020 -
Capitalization 40 336 M 40 336 M -
EV / Sales 2019 4,81x
EV / Sales 2020 5,62x
Nbr of Employees 3 837
Free-Float -
More Financials
Company
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on discovering, development and commercialization of medicines. The CompanyÔÇÖs marketed products include ULTOMIRIS, SOLIRIS (eculizumab), STRENSIQ (asfotase alfa), KANUMA (sebelipase alfa) and ANDEXXA (coagulation Factor Xa - [recombinant] inactivated-zhzo). Its ULTOMIRIS product is a long-acting C5 inhibitor, that works by... 
Sector
Pharmaceuticals
Calendar
-
More about the company
Ratings of Alexion Pharmaceuticals, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B-
More Ratings
All news about ALEXION PHARMACEUTICALS, INC.
07:09aThe 2022 PMPRB Outlook For Pharmaceutical Patentees In Canada
AQ
01/10AstraZeneca and Neurimmune sign exclusive global collaboration and licence agreement to..
AQ
01/07AstraZeneca and Neurimmune sign exclusive global collaboration and licence agreement to..
AQ
01/07Alexion Enters into an Exclusive Global Collaboration and Licence Agreement with Neurim..
CI
2021M&A market remains strong despite decline in activity
AQ
2021LIFE SCIENCES : Vavilov And The New Regulatory Environment
AQ
2021ALEXION PHARMACEUTICALS : Canada Seeks Leave To Appeal To The Supreme Court In PMPRB Exces..
AQ
2021Alexion Pharmaceuticals, Inc. completed the acquisition of remaining majority stake in ..
CI
2021OCULAR THERAPEUTIX : Announces appointment of karen-leigh edwards as senior vice president..
AQ
2021AstraZeneca's Alexion to Advance and Accelerate Ongoing Phase III Clinical Development ..
CI
2021Alexion Pharmaceuticals, Inc. agreed to acquire remaining majority stake in Caelum Bios..
CI
2021ASTRAZENECA : to Mandate COVID-19 Shots for US Staff
MT
2021ALEXION PHARMACEUTICALS : FCA Remits Pricing Decision On ALEXION'S SOLIRIS To PMPRB
AQ
2021ASTRAZENECA : Rare Disease Drug Improves Copper Mobilization in Late-Stage Study
MT
2021ALEXION PHARMACEUTICALS : Update on CHAMPION-ALS Phase III trial of Ultomiris in amyotroph..
AQ
More news
News in other languages on ALEXION PHARMACEUTICALS, INC.
01/07Alexion conclut un accord mondial exclusif de collaboration et de licence avec Neurimmu..
2021Astrazeneca tombe dans le rouge au 3e timestre, malgré le vaccin
2021AstraZeneca va rendre obligatoires les injections de COVID-19 pour le personnel américa..
2021Un médicament d'AstraZeneca contre les maladies rares améliore la mobilisation du cuivr..
2021AKTIEN EUROPA SCHLUSS : Freundlicher Wochenausklang dank US-Rückenwind
More news
Analyst Recommendations on ALEXION PHARMACEUTICALS, INC.
More recommendations
Chart ALEXION PHARMACEUTICALS, INC.
Duration : Period :
Alexion Pharmaceuticals, Inc. Technical Analysis Chart | ALXN | US0153511094 | MarketScreener
Income Statement Evolution
Managers and Directors
George Llado Chief Information Officer & Senior Vice President
Indrani M. Franchini Chief Compliance Officer & Executive VP
Rana Strellis SVP-Global Culture & Social Responsibility
Gianluca Pirozzi Head-Clinical Development, Hematology & Nephrology
Uzair Qadeer Chief Diversity Officer & Senior Vice President
Sector and Competitors